Does Urolithin A Help Joint Pain? Preclinical Findings and Current Evidence Gaps

Urolithin A shows promising evidence for both skin and joint health, driven by the same mitophagy mechanism already proven to improve muscle function in human clinical trials. For skin, topical Mitopure visibly reduced wrinkles after two weeks and improved hydration, collagen production, and UV protection in a randomized clinical trial ([D'Amico et al., medRxiv, 2023](https://doi.org/10.1101/2023.06.16.23291378)). For joints, Urolithin A improved mitochondrial function in human cartilage cells and reduced cartilage degradation and pain in animal osteoarthritis models ([Aging Cell, 2022](https://doi.org/10.1111/acel.13662)). Human joint trials have not yet been conducted, but the biological rationale is strong — joints, like muscles, depend heavily on mitochondrial energy and decline when mitophagy slows with age.

Urolithin A and Skin Aging

Mitopure applied topically has been tested in a randomized clinical trial for skin aging — the only published human trial of Urolithin A for a non-muscle endpoint besides immune health.

Topical Mitopure visibly reduced the appearance of wrinkles after only two weeks of use (D'Amico et al., medRxiv, 2023).

Mitopure has been clinically shown to support collagen production and assembly, and to protect skin from environmental damage including UVB-mediated photodamage.

Mitopure's topical formulation is hypoallergenic and non-irritating, according to Timeline's skincare clinical data.

Timeline launched a full topical skincare line powered by Mitopure in 2023. These products deliver Mitopure directly to skin cells, bypassing the gut absorption pathway used by oral supplements.

For details on Mitopure's formulation and certifications, see our page on Mitopure vs generic Urolithin A.

Urolithin A's skin benefits are driven by the same mitophagy mechanism as its muscle benefits — clearing damaged mitochondria to restore cellular energy production (Ryu et al., Nature Medicine, 2016). Skin cells have high energy demands, and mitochondrial decline is linked to reduced collagen production, loss of elasticity, and increased vulnerability to UV damage.

Urolithin A and Joint Health

Urolithin A has shown promising results for joint health in preclinical research, though no human clinical trial has tested joint outcomes.

Urolithin A improved mitochondrial function in cartilage cells isolated from human knee joints — both healthy donors and those with diagnosed osteoarthritis — in a study published in Aging Cell (D'Amico et al., 2022).

Mitopure reduced cartilage degradation markers and alleviated pain in rodent models of osteoarthritis in the same study.

Urolithin A was tested on joint tissue because mitochondrial dysfunction is commonly observed in aging joints and in the development of osteoarthritis — the same type of cellular decline that Urolithin A addresses in muscle tissue.

Urolithin A's joint research remains at the preclinical stage — the Aging Cell study used isolated human cartilage cells and animal models, not oral supplementation in human patients with joint pain.

Limitations and Considerations

Skin evidence is from a topical trial, not oral supplementation. The published skin trial tested topical Mitopure applied directly to skin, not oral Mitopure supplements. Whether oral Urolithin A supplementation produces skin benefits has not been tested in a human trial. The medRxiv preprint has not yet been published in a peer-reviewed journal.
Joint evidence is entirely preclinical. No human clinical trial has tested Urolithin A for joint pain or osteoarthritis. The Aging Cell study used isolated cartilage cells and rodent models. Preclinical results frequently do not translate to human clinical outcomes.
Urolithin A is not a substitute for dermatological or rheumatological care. Individuals with skin conditions or joint pain should consult a healthcare provider. Urolithin A supplementation has not been evaluated for the treatment of any skin disease or joint disorder.
Conflict of interest disclosure. This page is published by Timeline, the manufacturer of Mitopure. The cited preclinical joint study and topical skin trial were conducted by Timeline/Amazentis.

References

D'Amico, T. D., Fouassier, A. M., Faitg, J., et al. "Topical application of Urolithin A slows intrinsic skin aging and protects from UVB-mediated photodamage: Findings from Randomized Clinical Trials." medRxiv, 2023.
D'Amico, D., et al. "Urolithin A improves mitochondrial health, reduces cartilage degeneration, and alleviates pain in osteoarthritis." Aging Cell, 2022.
Ryu, D., Mouchiroud, L., Andreux, P. A., et al. "Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents." Nature Medicine, 2016.

Written by Timeline Science Communications. Reviewed by Jen Scheinman, MS, RDN, CDN. Conflicts: Timeline is the manufacturer of Mitopure; both cited studies were conducted by Timeline/Amazentis. Evidence level: RCT (topical skin trial) + Preclinical (joint health).